Emerging innovations in theranostics for pancreatic neuroendocrine tumors.

IF 6.8 1区医学 Q1 ONCOLOGY

NPJ Precision Oncology Pub Date : 2025-05-19 DOI:10.1038/s41698-025-00938-1

Anita Karimi, Christina Bogdani, Elisabeth O'Dwyer, Despina Siolas

引用次数: 0

Abstract

Pancreatic neuroendocrine tumors (pNETs) often overexpress somatostatin receptor type 2 (SSTR2), making them ideal targets for theranostics, which integrates molecular imaging with targeted radionuclide therapy. ¹⁷⁷Lu-DOTATATE significantly extends progression-free survival (22.8 vs. 8.5 months) compared to octreotide LAR. Despite these advances, challenges remain, including treatment resistance and long-term toxicities. In this review, we explore advancements in specialized imaging techniques, rationale combination strategies, and exploring next-generation radiopharmaceuticals.

查看原文本刊更多论文

胰腺神经内分泌肿瘤治疗的新进展。

胰腺神经内分泌肿瘤（pNETs）通常过度表达生长抑素受体2型（SSTR2），使其成为结合分子成像和靶向放射性核素治疗的理想治疗靶点。与奥曲肽LAR相比，lu - dotatate显著延长无进展生存期（22.8个月对8.5个月）。尽管取得了这些进展，但挑战依然存在，包括治疗耐药性和长期毒性。在这篇综述中，我们探讨了专业成像技术的进展，基本原理组合策略，并探索下一代放射性药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Precision Oncology ONCOLOGY-

CiteScore

9.90

自引率

1.30%

发文量

审稿时长

18 weeks

期刊介绍： Online-only and open access, npj Precision Oncology is an international, peer-reviewed journal dedicated to showcasing cutting-edge scientific research in all facets of precision oncology, spanning from fundamental science to translational applications and clinical medicine.